Ziphius is a biotechnology company focused on the development of self-amplifying RNA-based (saRNA) vaccines and therapeutics based on its proprietary saRNA and carrier technology (LNP) platform to allow for a higher and prolonged protein/antigen expression at lower doses (compared to conventional mRNA) with reduced toxicity. This platform has the potential for a ‘plug and play’ approach offering the possibility of fast development/scale-up and production. These attributes makes it well suited as platform to improve pandemic preparedness.